Brand Index Methodology
The Morning Consult Brand Index is an indicator of brand strength among consumers. Each Fortune 500 company receives a score based on a ratio of favorable to unfavorable impressions among U.S. adults and its overall favorability. This ensures that a score takes into account how well-liked a company is among people who have an opinion of it without penalizing companies that are not consumer-facing.
Morning Consult polls thousands of adults across the country each week. The surveys are conducted online using large, established online survey vendors. The data is weighted to approximate a nationally representative sample based on age, race/ethnicity, gender, educational attainment, region, annual household income, home ownership status and marital status.
The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year–an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy has been recently halted.
CEO
Kenneth C. Frazier
CEO Title
Chairman, President & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, N.J.
Website
Years on Fortune 500 List
24
Employees
69,000
SPONSOR CENTER
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $40,122 | 0.8% |
| Profits ($M) | $2,394.0 | -38.9% |
| Assets ($M) | $87,872 | |
| Total Stockholder Equity ($M) | $34,336 | |
| Market Value — as of March 29, 2018 ($M) | $146,862 |
| Profit as % of Revenues | 6.0% | |
| Profits as % of Assets | 2.7% | |
| Profits as % of Stockholder Equity | 7.0% |
| Earnings Per Share ($) | 0.87 | |
| EPS % Change (from 2016) | -38.3% | |
| EPS % Change (5 year annual rate) | -15.3% | |
| EPS % Change (10 year annual rate) | -5.2% |
| Total Return to Investors (2017) | -1.5% | |
| Total Return to Investors (5 year, annualized) | 10.1% | |
| Total Return to Investors (10 year, annualized) | 3.5% |
- Previous Close:
- Market Cap: NaNB
- Next Earnings Date:
- High:
- Low:
- 52 Week High:
- 52 Week Low:
- 52 Week Change %: 0.00
- P/E Ratio: n/a
- EPS:
- Dividend Yield: n/a
News about Merck
With more than two dozen new deaths reported, Ebola spreads across the Congo. Is there a new weapon to stop it?
Must-read business news, delivered every morning.
Pfizer stock was down more than 4%, while Merck fell 2% despite beating profit expectations.
This year's list is all about new power. Number one? The kids of Marjory Stoneman Douglas High School.
Must-read business news, delivered every morning.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc.. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions